The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia

Mise à jour : Il y a 5 ans
Référence : NCT01101295

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.


Critère d'inclusion

  • Purpura, Thrombocytopenic, Idiopathic ,Autoimmune Thrombocytopenia

Liens